Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NFRX nice forecast
Here's a nice forecast .... Link http://www.cpreports.com/?p=861
You Are Here: Home » CP Reports Blog » RAY DIRKS Research: NFRX.pk Feb 8, 2011 by Ray Dirks
RAY DIRKS Research: NFRX.pk Feb 8, 2011 by Ray Dirks
Posted on admin on February 9, 2011 // Leave Your Comment InferX Corporation (NFRX.pk) – $0.60
February 7, 2011
RAY DIRKS Research recommends InferX Corporation (NFRX.pk) at its current price of 60 cents per share for substantial capital appreciation over the next 6 months, 1 year, 3 years, and 5 years. Headquartered in Northern Virginia near the Dulles International airport, InferX’s top management team and its 25 full-time employees plus 30 consultants are capable of leading the accelerating worldwide trend of Predictive Analysis (PA) by utilizing its 6 key patents (2 granted and 4 pending) in such significant areas as healthcare, insurance, government, finance, retail, and sales and marketing of industrial products.
Specifically, RAY DIRKS Research believes that the common stock of InferX will appreciate by 100% within 3 months to $1.20, triple within 1 year to $1.80, appreciate by 10 times within 3 years to $6.00, and by 20 times within 5 years to $12.00 per share.
Because InferX is pioneering a next-generation technology and currently has modest revenues, we recommend that investors commit no more than 1 percent of their equity portfolio to NFRX common shares. Just last week InferX stock advanced sharply because of an announcement concerning a significant contract.
Summary Financial Table for InferX (NFRX.ob):
Current Price $0.60
Target Price May 10, 2011 $1.20
Target Price February 10, 2012 $1.80
Target Price February 10, 2014 $6.00
Target price February 10, 2016 $12.00
Shares Outstanding 17.3 million
Shares Fully Diluted 29.4 million
Market Capitalization $ 10.4 million
Est. Earnings per Share – 2011 $ -0.02
Est. Cash Flow per Share – 2011 $ 0.01
InferX (NFRX) is a market leader in next-generation distributed Predictive Analytics (PA) software solutions. InferX pioneered and commercialized a powerful, patented group of advanced analytical solutions which direct decision making and improve corporate performance. InferX targets its sophisticated solution toward select sub-sectors in the healthcare, public sector, industrial product, retail, and financial service industries in order to address significant Return on Investment opportunities.
PA enterprise software solutions directs decision making by applying advanced analytics and decision organization to a client organization’s enterprise data, with the objective of improving the client’s business processes to meet its specific organization goals. The PA solution accomplishes this through the application of advanced algorithms that process historical data, “learn” what has occurred in the past, and create “real time” business decisions within the client’s organization.
Traditional business intelligence (BI) tools extract relevant data in a structured way, aggregate and present it in formats such as dashboards and reports. BI tools are more exploratory than decision-oriented, helping businesses understand performance and trend, but generally not directing future actions or decisions based on what has been observed. Any attempts at using BI platforms to offer predictive insights are based on “deductive” technology (i.e., regression analysis) where “experts” create initial rules or hypotheses about the patterns and relationships that exist within the data based on their personal experience (i.e., who is a credit risk, what parameters create a potential risk, what medical indicators suggest a possible adverse drug reaction, etc.). Therefore, decisions based on a deductive approach are only as good as the initial rules, hypotheses, or data variables that directed the analysis.
By contrast, Predictive Analysis enterprise software solutions are based on “inductive” technology. PA does not presume initial rules or hypotheses about patterns and relationships that could exist within the data. Rather, PA lets data lead the way and employs statistics, machine learning, neural computing, robotics, computational mathematics, and artificial intelligence techniques to explore all the data, instead of utilizing a narrow subset of it, to ferret out meaningful relationships and patterns. This approach allows PA to identify insights and relationships among different variables, particularly ones that are outside conventional thinking.
InferX’s next-generation PA solution differentiates itself from traditional PA solutions in that it operates best in a distributed data environment. Instead of having to move data from different locations and servers into data warehouses to perform analysis, the next generation distributive PA solution brings the analysis directly to the data. InferX’s distributed solution is patented and enhances analytical speed, data privacy, and security while reducing cost.
In 2009, InferX merged with the Irus Group, a BI consulting and services firm specializing in the planning, implementation, and development of complex BI and corporate performance management solutions for government, financial services, retail, and healthcare clients. Since its founding, Irus Group has conducted engagements for over 200 clients, including Master Card, JPMorgan Chase, ConAgra, US Navy, US Army, US Air Force, and Peace Corps. The merger provides InferX additional financial support in advance of the full roll-out of InferX’s enterprise software solutions, and it serves as a valuable source of sales leads for the PA enterprise software product.
Disclosure:
The information contained in this Report contains forward-looking statements relating to the developments of the featured company’s products, services and future operating results or the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected.
The words “believe,”, “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect performance include, but are not limited to, those factors that are discussed in each Company’s most recent reports and/or registration statements filed with the Securities and Exchange Commission. Visitors to this Internet Site are cautioned not to place undue reliance on these forward-looking statements. These statements have not been independently verified by the officers, directors or employees of Corporate Profile, LLC .com.
The information on this Internet Site has been submitted by journalists and analysts or provided by the companies contained herein or other sources believed to be reliable. Corporate Profile, LLC has not independently verified the information provided to it by third parties. Each individual should perform his or her own independent analysis before investing. The information contained herein is neither an offer nor a solicitation to buy any of the securities of the companies contained herein. Investing in securities is speculative and contains a high element of risk.
NFRX nice forecast
Here's a nice forecast .... Link http://www.cpreports.com/?p=861
You Are Here: Home » CP Reports Blog » RAY DIRKS Research: NFRX.pk Feb 8, 2011 by Ray Dirks
RAY DIRKS Research: NFRX.pk Feb 8, 2011 by Ray Dirks
Posted on admin on February 9, 2011 // Leave Your Comment InferX Corporation (NFRX.pk) – $0.60
February 7, 2011
RAY DIRKS Research recommends InferX Corporation (NFRX.pk) at its current price of 60 cents per share for substantial capital appreciation over the next 6 months, 1 year, 3 years, and 5 years. Headquartered in Northern Virginia near the Dulles International airport, InferX’s top management team and its 25 full-time employees plus 30 consultants are capable of leading the accelerating worldwide trend of Predictive Analysis (PA) by utilizing its 6 key patents (2 granted and 4 pending) in such significant areas as healthcare, insurance, government, finance, retail, and sales and marketing of industrial products.
Specifically, RAY DIRKS Research believes that the common stock of InferX will appreciate by 100% within 3 months to $1.20, triple within 1 year to $1.80, appreciate by 10 times within 3 years to $6.00, and by 20 times within 5 years to $12.00 per share.
Because InferX is pioneering a next-generation technology and currently has modest revenues, we recommend that investors commit no more than 1 percent of their equity portfolio to NFRX common shares. Just last week InferX stock advanced sharply because of an announcement concerning a significant contract.
Summary Financial Table for InferX (NFRX.ob):
Current Price $0.60
Target Price May 10, 2011 $1.20
Target Price February 10, 2012 $1.80
Target Price February 10, 2014 $6.00
Target price February 10, 2016 $12.00
Shares Outstanding 17.3 million
Shares Fully Diluted 29.4 million
Market Capitalization $ 10.4 million
Est. Earnings per Share – 2011 $ -0.02
Est. Cash Flow per Share – 2011 $ 0.01
InferX (NFRX) is a market leader in next-generation distributed Predictive Analytics (PA) software solutions. InferX pioneered and commercialized a powerful, patented group of advanced analytical solutions which direct decision making and improve corporate performance. InferX targets its sophisticated solution toward select sub-sectors in the healthcare, public sector, industrial product, retail, and financial service industries in order to address significant Return on Investment opportunities.
PA enterprise software solutions directs decision making by applying advanced analytics and decision organization to a client organization’s enterprise data, with the objective of improving the client’s business processes to meet its specific organization goals. The PA solution accomplishes this through the application of advanced algorithms that process historical data, “learn” what has occurred in the past, and create “real time” business decisions within the client’s organization.
Traditional business intelligence (BI) tools extract relevant data in a structured way, aggregate and present it in formats such as dashboards and reports. BI tools are more exploratory than decision-oriented, helping businesses understand performance and trend, but generally not directing future actions or decisions based on what has been observed. Any attempts at using BI platforms to offer predictive insights are based on “deductive” technology (i.e., regression analysis) where “experts” create initial rules or hypotheses about the patterns and relationships that exist within the data based on their personal experience (i.e., who is a credit risk, what parameters create a potential risk, what medical indicators suggest a possible adverse drug reaction, etc.). Therefore, decisions based on a deductive approach are only as good as the initial rules, hypotheses, or data variables that directed the analysis.
By contrast, Predictive Analysis enterprise software solutions are based on “inductive” technology. PA does not presume initial rules or hypotheses about patterns and relationships that could exist within the data. Rather, PA lets data lead the way and employs statistics, machine learning, neural computing, robotics, computational mathematics, and artificial intelligence techniques to explore all the data, instead of utilizing a narrow subset of it, to ferret out meaningful relationships and patterns. This approach allows PA to identify insights and relationships among different variables, particularly ones that are outside conventional thinking.
InferX’s next-generation PA solution differentiates itself from traditional PA solutions in that it operates best in a distributed data environment. Instead of having to move data from different locations and servers into data warehouses to perform analysis, the next generation distributive PA solution brings the analysis directly to the data. InferX’s distributed solution is patented and enhances analytical speed, data privacy, and security while reducing cost.
In 2009, InferX merged with the Irus Group, a BI consulting and services firm specializing in the planning, implementation, and development of complex BI and corporate performance management solutions for government, financial services, retail, and healthcare clients. Since its founding, Irus Group has conducted engagements for over 200 clients, including Master Card, JPMorgan Chase, ConAgra, US Navy, US Army, US Air Force, and Peace Corps. The merger provides InferX additional financial support in advance of the full roll-out of InferX’s enterprise software solutions, and it serves as a valuable source of sales leads for the PA enterprise software product.
Disclosure:
The information contained in this Report contains forward-looking statements relating to the developments of the featured company’s products, services and future operating results or the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected.
The words “believe,”, “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect performance include, but are not limited to, those factors that are discussed in each Company’s most recent reports and/or registration statements filed with the Securities and Exchange Commission. Visitors to this Internet Site are cautioned not to place undue reliance on these forward-looking statements. These statements have not been independently verified by the officers, directors or employees of Corporate Profile, LLC .com.
The information on this Internet Site has been submitted by journalists and analysts or provided by the companies contained herein or other sources believed to be reliable. Corporate Profile, LLC has not independently verified the information provided to it by third parties. Each individual should perform his or her own independent analysis before investing. The information contained herein is neither an offer nor a solicitation to buy any of the securities of the companies contained herein. Investing in securities is speculative and contains a high element of risk.
Here's a nice forecast .... Link http://www.cpreports.com/?p=861
You Are Here: Home » CP Reports Blog » RAY DIRKS Research: NFRX.pk Feb 8, 2011 by Ray Dirks
RAY DIRKS Research: NFRX.pk Feb 8, 2011 by Ray Dirks
Posted on admin on February 9, 2011 // Leave Your Comment InferX Corporation (NFRX.pk) – $0.60
February 7, 2011
RAY DIRKS Research recommends InferX Corporation (NFRX.pk) at its current price of 60 cents per share for substantial capital appreciation over the next 6 months, 1 year, 3 years, and 5 years. Headquartered in Northern Virginia near the Dulles International airport, InferX’s top management team and its 25 full-time employees plus 30 consultants are capable of leading the accelerating worldwide trend of Predictive Analysis (PA) by utilizing its 6 key patents (2 granted and 4 pending) in such significant areas as healthcare, insurance, government, finance, retail, and sales and marketing of industrial products.
Specifically, RAY DIRKS Research believes that the common stock of InferX will appreciate by 100% within 3 months to $1.20, triple within 1 year to $1.80, appreciate by 10 times within 3 years to $6.00, and by 20 times within 5 years to $12.00 per share.
Because InferX is pioneering a next-generation technology and currently has modest revenues, we recommend that investors commit no more than 1 percent of their equity portfolio to NFRX common shares. Just last week InferX stock advanced sharply because of an announcement concerning a significant contract.
Summary Financial Table for InferX (NFRX.ob):
Current Price $0.60
Target Price May 10, 2011 $1.20
Target Price February 10, 2012 $1.80
Target Price February 10, 2014 $6.00
Target price February 10, 2016 $12.00
Shares Outstanding 17.3 million
Shares Fully Diluted 29.4 million
Market Capitalization $ 10.4 million
Est. Earnings per Share – 2011 $ -0.02
Est. Cash Flow per Share – 2011 $ 0.01
InferX (NFRX) is a market leader in next-generation distributed Predictive Analytics (PA) software solutions. InferX pioneered and commercialized a powerful, patented group of advanced analytical solutions which direct decision making and improve corporate performance. InferX targets its sophisticated solution toward select sub-sectors in the healthcare, public sector, industrial product, retail, and financial service industries in order to address significant Return on Investment opportunities.
PA enterprise software solutions directs decision making by applying advanced analytics and decision organization to a client organization’s enterprise data, with the objective of improving the client’s business processes to meet its specific organization goals. The PA solution accomplishes this through the application of advanced algorithms that process historical data, “learn” what has occurred in the past, and create “real time” business decisions within the client’s organization.
Traditional business intelligence (BI) tools extract relevant data in a structured way, aggregate and present it in formats such as dashboards and reports. BI tools are more exploratory than decision-oriented, helping businesses understand performance and trend, but generally not directing future actions or decisions based on what has been observed. Any attempts at using BI platforms to offer predictive insights are based on “deductive” technology (i.e., regression analysis) where “experts” create initial rules or hypotheses about the patterns and relationships that exist within the data based on their personal experience (i.e., who is a credit risk, what parameters create a potential risk, what medical indicators suggest a possible adverse drug reaction, etc.). Therefore, decisions based on a deductive approach are only as good as the initial rules, hypotheses, or data variables that directed the analysis.
By contrast, Predictive Analysis enterprise software solutions are based on “inductive” technology. PA does not presume initial rules or hypotheses about patterns and relationships that could exist within the data. Rather, PA lets data lead the way and employs statistics, machine learning, neural computing, robotics, computational mathematics, and artificial intelligence techniques to explore all the data, instead of utilizing a narrow subset of it, to ferret out meaningful relationships and patterns. This approach allows PA to identify insights and relationships among different variables, particularly ones that are outside conventional thinking.
InferX’s next-generation PA solution differentiates itself from traditional PA solutions in that it operates best in a distributed data environment. Instead of having to move data from different locations and servers into data warehouses to perform analysis, the next generation distributive PA solution brings the analysis directly to the data. InferX’s distributed solution is patented and enhances analytical speed, data privacy, and security while reducing cost.
In 2009, InferX merged with the Irus Group, a BI consulting and services firm specializing in the planning, implementation, and development of complex BI and corporate performance management solutions for government, financial services, retail, and healthcare clients. Since its founding, Irus Group has conducted engagements for over 200 clients, including Master Card, JPMorgan Chase, ConAgra, US Navy, US Army, US Air Force, and Peace Corps. The merger provides InferX additional financial support in advance of the full roll-out of InferX’s enterprise software solutions, and it serves as a valuable source of sales leads for the PA enterprise software product.
Disclosure:
The information contained in this Report contains forward-looking statements relating to the developments of the featured company’s products, services and future operating results or the future of the market. Statements contained in writing or in interviews are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected.
The words “believe,”, “expect,” “intend,” “anticipate,” variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect performance include, but are not limited to, those factors that are discussed in each Company’s most recent reports and/or registration statements filed with the Securities and Exchange Commission. Visitors to this Internet Site are cautioned not to place undue reliance on these forward-looking statements. These statements have not been independently verified by the officers, directors or employees of Corporate Profile, LLC .com.
The information on this Internet Site has been submitted by journalists and analysts or provided by the companies contained herein or other sources believed to be reliable. Corporate Profile, LLC has not independently verified the information provided to it by third parties. Each individual should perform his or her own independent analysis before investing. The information contained herein is neither an offer nor a solicitation to buy any of the securities of the companies contained herein. Investing in securities is speculative and contains a high element of risk.
your bid is most likely behind ETMM who may have a large order to fill
The real question you have to ask yourself is WHO is collecting these shares at .0001 and WHY? If this is a bust who would be accumulating at .0001?
I only have the free membership, I was hoping someone could Print screen then post to see, but thanks anyway
Can anyone Post a current L2 Screen shot
Can someone Post a SCREENSHOT, I will then call ETRADE and question them with this in hand
If that's the case, can you post a snapshot of that screen please
Is there anyway to tell which mm's or brokerages are buying the shares which are trading today, to see if ETRADE has bought any of the .0001's or .0002's that have been traded today? Does anyone know?
I think any volume at the ask this will go this time around
all I know is what everyone else knows, tons of shares have been traded at .0002 without a rise in the price, doesn't seem possible to me, if there was ever a shorting situation it seems as though this is a prime case, jmo
we'll see time will tell, right
They want you to SELL at .0001 so they can cover, everyone knows they have been selling shares they don't have, how else could this have stayed at .0002 for all this time, think about it people
I believe you are 100% correct
I'm with you any buying volume and this thing finally goes, they are getting rel desperate
maybe they will make them cover if they are short, who knows
3 @ .60, then $4.99, LOL
PR TIME
10-20,000 per trade is what you're talking about and how many times along the way, i don't know off hand, twenty or more
amazing to me too, I would love to see some amazing validation soon
People chase so many awful plays, I'm surprised there are not more here on this one, just a handful, unbelievable
Funny thing about the buyer, he always raises the ask when he buys so they cannot flip it seemingly.
How about something about their first Commercial Contract, that would be a great PR, here's to wishful thinking
No dought the PERFECT OPPORTUNITY if they ever wanted to get this above a dollar.
NFRX, 1 left at .59, then .99
NFRX, 2 Left at .59, then break out nothing til $2
NFRX, 16 Mil Float, up 25% Dollar Break Coming then new buyers
NFRX, Contract NEWS out
A Little volume and this thing busts over a dollar
Nite moved from .59 to 2.00
Yeah, I would love to see a contract from the public sector, I really believe that would get the ball rolling.
Nice news more contacts
.0003's have surfaced on the ask now
yeah, like 15 Million in the last 2 buys
well you saw about a month ago there were (2) different 350,000 share trades a week apart
First buy of the day $23500 , 50,000 shares at the ask .47
amazing to me
Follow the MONEY
So what are u saying Stoli? Are we going to Dollars soon or back to single pennies? What do ya think?
Maybe some late action
I would love to see the new PR firm jump into action soon.
If this ever breaks .60 it could be blue skys ahead big time